Effect of vitamin E supplementation on antibody levels against malondialdehyde modified LDL in hyperlipidemic hamsters

Cardiovascular Research

Volumn 47, Issue 3, 2000, Pages 567-573

  De Oliveira, Fernando G ^a   Rossi, Cláudio L ^a   De Oliveira, Marcelo G ^a   Saad, Mário J A ^a   Velloso, Lício A ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Atherosclerosis; Cholesterol; Free radicals; Lipoproteins

Indexed keywords

ALPHA TOCOPHEROL; AUTOANTIBODY; CHOLESTEROL; FREE RADICAL; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; TRIACYLGLYCEROL;

ADOLESCENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HAMSTER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERLIPIDEMIA; LIPID OXIDATION; MALE; NONHUMAN; PRIORITY JOURNAL; SPECTROFLUOROMETRY; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

ANALYSIS OF VARIANCE; ANIMALS; AUTOANTIBODIES; CHOLESTEROL; CRICETINAE; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HYPERLIPIDEMIAS; LIPID PEROXIDATION; LIPIDS; LIPOPROTEINS, LDL; MALE; MALONDIALDEHYDE; SPECTROMETRY, FLUORESCENCE; TRIGLYCERIDES; VITAMIN E;

EID: 0034683024     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(00)00121-8     Document Type: Article

References (36)

1. Ylä -Herttuala S., Palinski W., Rosenfeld M.E., et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 84:1989;1086-1095.
2. Rosenfeld M.E., Palinski W., Ylä-Herttuala S., et al. Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis. 10:1990;336-349.
3. Boyd H.C., Gown A.M., Wolfbauer G., et al. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a watanabe heritable hyperlipidemic rabbit. Am J Pathol. 135:1989;815-825.
4. Klimov A. In vivo formation of modified lipoproteins with increase affinity for macrophages. Atheroscler Rev. 17:1988;75-86.
5. Palinski W., Hörkkö S., Miller E., et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. J Clin Invest. 98:1996;800-814.
6. Quinn M.T., Parthasarathy S., Fong L.G., et al. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA. 84:1987;2995-2998.
7. Quinn M.T., Parthasarathy S., Steinberg D., et al. Endothelial cell-derived chemotactic activity for mouse peritoneal macrophages and the effects of modified forms of low density lipoprotein. Proc Natl Acad Sci USA. 82:1985;5949-5953.
8. Morel D.W., Dicorleto P.E., Chisolm G.M., et al. Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis. 4:1984;356-364.
9. Hessler J.R., Robertson A.L. Jr., Chisolm G.M., et al. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis. 32:1979;213-229.
10. Witztum J.L., Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 88:1991;1785-1792.
11. Palinski W., Tangirala R.K., Miller E., et al. Increased autoantibody titers against epitopes of oxidized LDL in receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol. 15:1995;1569-1576.
12. Salonen J.T., YläHerttuala S., Yamamoto R., et al. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet. 339:1992;883-887.
13. Bergmark C., Wu R., Faire U., et al. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol. 15:1995;441-445.
14. Bellomo G., Maggi E., Poli M., et al. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM. Diabetes. 44:1995;60-66.
15. Puurunen M., Mänttäri M., Manninen V., et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med. 154:1994;2605-2609.
16. Jürgens G., Hoff H.F., Chisolm G.M., Esterbauer H. Modification of human serum LDL by oxidation - characterization and pathophysiological implications. Chem Phys Lipids. 45:1987;315-336.
17. Prasad K., Kalra J. Oxygen free radicals and hypercholesterolemic atherosclerosis: effect of vitamin E. Am Heart J. 125:1993;958-973.
18. Jialal I., Grundy S.M. Effect of combined supplementation with α-tocopherol, ascorbate and β carotene on low-density lipoprotein oxidation. Circulation. 88:1993;2780-2786.
19. Stephens N.G., Parsons A., Schofield P.M., et al. Randomized controlled trial of vitamin E in patients with coronary disease Cambridge Heart Antioxidant Study (CHAOS). Lancet. 347:1996;781-786.
20. Holvoet P., Perez G., Zhao Z., et al. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest. 95:1995;2611-2619.
21. Palinski W., Ylä-herttuala S., Rosenfeld M.E., et al. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis. 10:1990;325-335.
22. Stewart-Lee A.L., Forster L.A., Nourooz-Zadeh J., et al. Vitamin E protects against impairment of endothelium-mediated relaxations in cholesterol-fed rabbits. Arterioscler Thromb. 14:1994;494-499.
23. Hulthe J., Wikstrand J., Lidell A., et al. Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 18:1998;1203-1211.
24. Chen M.F., Hsu H.C., Lee Y.T., et al. Short-term treatment with low-dose pravastatin attenuates oxidative susceptibility of low-density lipoprotein in hypercholesterolemic patients. Cardiovasc Drugs Ther. 11:1997;787-793.
25. Meydani S.M., Meydani M., Blumberg J.B., et al. Vitamin E supplementation and in vivo immune response in healthy elderly subjects. J Am Med Assoc. 277:1997;1380-1386.
26. Orekhov A.N., Tertov V.V., Kabakov A.E., et al. Autoantibodies against modified low density lipoprotein: nonlipid factor of blood plasma that stimulates foam cell formation. Arterioscler Thromb. 11:1991;316-326.
27. Klimov A.N., Denisenko A.D., Vinogradov A.G., et al. Accumulation of cholesteryl esters in macrophages incubated with human lipoprotein-antibody autoimmune complex. Atherosclerosis. 74:1988;41-46.
28. Ameli S., Hultgardh-Nilsson A., Regniström J. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol. 16:1996;1074-1079.
29. Palinski W., Miller E., Witztum J.L., et al. Immunization of LDL receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA. 92:1995;821-825.
30. Virella G., Mironova M., Lopes-Virella M., et al. Comparing assays of antibodies to modified low-density lipoproteins. Clin Chem. 41:1995;324-325.
31. Mironova M., Virella G., Lopes-Virella M.F., et al. Isolation and characterization of human antioxidized LDL autoantibodies. Arterioscler Thromb Vasc Biol. 16:1996;222-229.
32. Shoulson I. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group: deprenyl and tocopherol antioxidant therapy of Parkinson. Ann Neurol. 44:(3):1998;S160-166.
33. Sano M., Ernesto C., Thomas R.G., et al. A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease cooperative study. New Engl J Med. 336:1997;1216-1222.
34. Stampfer M.J., Hennekens C.H., Manson J.E., et al. Vitamin E consumption and the risk of coronary disease in women. New Engl J Med. 328:1993;14449.
35. Ohrvall M., Berglund L., Salminen I., et al. The serum cholesterol ester fatty acid composition but not the serum concentration of α-tocopherol predicts the development of myocardial infarction in 50-year-old men: 19 years follow-up. Atherosclerosis. 127:1996;65-71.
36. Porkkala-Sarataho E., Nyyssonen K., Salonen J.T., et al. Increased oxidation resistance of atherogenic plasma lipoproteins at high vitamin E levels in non-vitamin E supplemented men. Atherosclerosis. 124:1996;83-94.